Compare FURY & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FURY | CNTB |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.0M | 135.7M |
| IPO Year | 2011 | 2020 |
| Metric | FURY | CNTB |
|---|---|---|
| Price | $0.67 | $2.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.70 | ★ $8.67 |
| AVG Volume (30 Days) | 212.2K | ★ 345.5K |
| Earning Date | 08-11-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.48 | $1.23 |
| 52 Week High | $1.02 | $3.82 |
| Indicator | FURY | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 70.33 | 51.02 |
| Support Level | $0.66 | $2.30 |
| Resistance Level | $0.72 | $2.69 |
| Average True Range (ATR) | 0.03 | 0.16 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 96.79 | 45.00 |
Fury Gold Mines Ltd is a Canadian-focused high-grade gold exploration company. The company's projects are strategically positioned in two prolific mining regions: the Eeyou Istchee James Bay Region of Quebec and the Kitikmeot Region in Nunavut. Fury Gold's project portfolio comprises the Committee Bay gold project in Nunavut, and the Eau Claire gold, Sakami gold, Elmer East gold and lithium, and Eleonore South gold projects in Quebec. Additionally, it also owns interests in the Kipawa rare earths project and has full ownership of the Zeus heavy rare earths project, both located in the Temiscamingue region of Quebec. The company operates in two reportable segments: Quebec and Nunavut.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.